NMR Metabolomics Protocols for Drug Discovery

Fatema Bhinderwala, Robert Powers

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Drug discovery is an extremely difficult and challenging endeavor with a very high failure rate. The task of identifying a drug that is safe, selective, and effective is a daunting proposition because disease biology is complex and highly variable across patients. Metabolomics enables the discovery of disease biomarkers, which provides insights into the molecular and metabolic basis of disease and may be used to assess treatment prognosis and outcome. In this regard, metabolomics has evolved to become an important component of the drug discovery process to resolve efficacy and toxicity issues and as a tool for precision medicine. A detailed description of an experimental protocol is presented that outlines the application of NMR metabolomics to the drug discovery pipeline. This includes (1) target identification by understanding the metabolic dysregulation in diseases, (2) predicting the mechanism of action of newly discovered or existing drug therapies, (3) and using metabolomics to screen a chemical lead to assess biological activity. Unlike other OMICS approaches, the metabolome is “fragile” and may be negatively impacted by improper sample collection, storage, and extraction procedures. Similarly, biologically irrelevant conclusions may result from incorrect data collection, preprocessing or processing procedures, or the erroneous use of univariate and multivariate statistical methods. These critical concerns are also addressed in the protocol.

Original languageEnglish (US)
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages265-311
Number of pages47
DOIs
StatePublished - Jan 1 2019

Publication series

NameMethods in Molecular Biology
Volume2037
ISSN (Print)1064-3745
ISSN (Electronic)1940-6029

Fingerprint

Metabolomics
Drug Discovery
Precision Medicine
Metabolome
Metabolic Diseases
Biomarkers
Drug Therapy
Pharmaceutical Preparations

Keywords

  • Chemometrics
  • Drug discovery
  • Metabolomics
  • NMR

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Bhinderwala, F., & Powers, R. (2019). NMR Metabolomics Protocols for Drug Discovery. In Methods in Molecular Biology (pp. 265-311). (Methods in Molecular Biology; Vol. 2037). Humana Press Inc.. https://doi.org/10.1007/978-1-4939-9690-2_16

NMR Metabolomics Protocols for Drug Discovery. / Bhinderwala, Fatema; Powers, Robert.

Methods in Molecular Biology. Humana Press Inc., 2019. p. 265-311 (Methods in Molecular Biology; Vol. 2037).

Research output: Chapter in Book/Report/Conference proceedingChapter

Bhinderwala, F & Powers, R 2019, NMR Metabolomics Protocols for Drug Discovery. in Methods in Molecular Biology. Methods in Molecular Biology, vol. 2037, Humana Press Inc., pp. 265-311. https://doi.org/10.1007/978-1-4939-9690-2_16
Bhinderwala F, Powers R. NMR Metabolomics Protocols for Drug Discovery. In Methods in Molecular Biology. Humana Press Inc. 2019. p. 265-311. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-4939-9690-2_16
Bhinderwala, Fatema ; Powers, Robert. / NMR Metabolomics Protocols for Drug Discovery. Methods in Molecular Biology. Humana Press Inc., 2019. pp. 265-311 (Methods in Molecular Biology).
@inbook{12657b1811994426a18de9806152749f,
title = "NMR Metabolomics Protocols for Drug Discovery",
abstract = "Drug discovery is an extremely difficult and challenging endeavor with a very high failure rate. The task of identifying a drug that is safe, selective, and effective is a daunting proposition because disease biology is complex and highly variable across patients. Metabolomics enables the discovery of disease biomarkers, which provides insights into the molecular and metabolic basis of disease and may be used to assess treatment prognosis and outcome. In this regard, metabolomics has evolved to become an important component of the drug discovery process to resolve efficacy and toxicity issues and as a tool for precision medicine. A detailed description of an experimental protocol is presented that outlines the application of NMR metabolomics to the drug discovery pipeline. This includes (1) target identification by understanding the metabolic dysregulation in diseases, (2) predicting the mechanism of action of newly discovered or existing drug therapies, (3) and using metabolomics to screen a chemical lead to assess biological activity. Unlike other OMICS approaches, the metabolome is “fragile” and may be negatively impacted by improper sample collection, storage, and extraction procedures. Similarly, biologically irrelevant conclusions may result from incorrect data collection, preprocessing or processing procedures, or the erroneous use of univariate and multivariate statistical methods. These critical concerns are also addressed in the protocol.",
keywords = "Chemometrics, Drug discovery, Metabolomics, NMR",
author = "Fatema Bhinderwala and Robert Powers",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/978-1-4939-9690-2_16",
language = "English (US)",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "265--311",
booktitle = "Methods in Molecular Biology",

}

TY - CHAP

T1 - NMR Metabolomics Protocols for Drug Discovery

AU - Bhinderwala, Fatema

AU - Powers, Robert

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Drug discovery is an extremely difficult and challenging endeavor with a very high failure rate. The task of identifying a drug that is safe, selective, and effective is a daunting proposition because disease biology is complex and highly variable across patients. Metabolomics enables the discovery of disease biomarkers, which provides insights into the molecular and metabolic basis of disease and may be used to assess treatment prognosis and outcome. In this regard, metabolomics has evolved to become an important component of the drug discovery process to resolve efficacy and toxicity issues and as a tool for precision medicine. A detailed description of an experimental protocol is presented that outlines the application of NMR metabolomics to the drug discovery pipeline. This includes (1) target identification by understanding the metabolic dysregulation in diseases, (2) predicting the mechanism of action of newly discovered or existing drug therapies, (3) and using metabolomics to screen a chemical lead to assess biological activity. Unlike other OMICS approaches, the metabolome is “fragile” and may be negatively impacted by improper sample collection, storage, and extraction procedures. Similarly, biologically irrelevant conclusions may result from incorrect data collection, preprocessing or processing procedures, or the erroneous use of univariate and multivariate statistical methods. These critical concerns are also addressed in the protocol.

AB - Drug discovery is an extremely difficult and challenging endeavor with a very high failure rate. The task of identifying a drug that is safe, selective, and effective is a daunting proposition because disease biology is complex and highly variable across patients. Metabolomics enables the discovery of disease biomarkers, which provides insights into the molecular and metabolic basis of disease and may be used to assess treatment prognosis and outcome. In this regard, metabolomics has evolved to become an important component of the drug discovery process to resolve efficacy and toxicity issues and as a tool for precision medicine. A detailed description of an experimental protocol is presented that outlines the application of NMR metabolomics to the drug discovery pipeline. This includes (1) target identification by understanding the metabolic dysregulation in diseases, (2) predicting the mechanism of action of newly discovered or existing drug therapies, (3) and using metabolomics to screen a chemical lead to assess biological activity. Unlike other OMICS approaches, the metabolome is “fragile” and may be negatively impacted by improper sample collection, storage, and extraction procedures. Similarly, biologically irrelevant conclusions may result from incorrect data collection, preprocessing or processing procedures, or the erroneous use of univariate and multivariate statistical methods. These critical concerns are also addressed in the protocol.

KW - Chemometrics

KW - Drug discovery

KW - Metabolomics

KW - NMR

UR - http://www.scopus.com/inward/record.url?scp=85071621837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071621837&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-9690-2_16

DO - 10.1007/978-1-4939-9690-2_16

M3 - Chapter

C2 - 31463851

AN - SCOPUS:85071621837

T3 - Methods in Molecular Biology

SP - 265

EP - 311

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -